Utah Medical Products financials
$74.95+0.62%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.5M | $8.7M | $9.0M | $9.8M | $10.0M | $9.7M | $9.2M | $10.0M | $10.4M | $11.3M | $12.3M | $12.5M |
| Gross profit | $4.8M | $5.3M | $5.3M | $5.6M | $5.6M | $5.5M | $5.3M | $5.8M | $6.3M | $6.8M | $7.1M | $7.4M |
| Gross margin | 55.8% | 60.6% | 58.2% | 57.1% | 56.2% | 57.0% | 58.1% | 58.0% | 60.1% | 59.7% | 57.6% | 58.8% |
| Operating income | $2.6M | $2.6M | $2.4M | $2.6M | $3.2M | $3.2M | $2.9M | $3.3M | $3.4M | $3.9M | $3.9M | $4.0M |
| Net income | $2.7M | $2.6M | $2.6M | $2.6M | $3.0M | $3.0M | $2.9M | $3.6M | $3.5M | $4.0M | $4.3M | $3.9M |
| Net margin | 31.5% | 29.9% | 28.4% | 26.8% | 30.6% | 31.3% | 31.7% | 35.6% | 33.2% | 34.9% | 34.8% | 31.5% |
| Diluted EPS | $0.84 | $0.82 | $0.80 | $0.82 | $0.94 | $0.92 | $0.86 | $1.02 | $0.98 | $1.09 | $1.18 | $1.08 |
| EBITDA | $2.9M | $3.2M | $3.2M | $3.4M | $3.9M | $3.9M | $3.6M | $4.1M | $4.1M | $4.6M | $3.9M | $5.7M |
| Operating cash flow | $1.4M | $3.1M | $3.5M | $3.9M | $2.9M | $4.5M | $2.9M | $3.9M | $2.8M | $5.3M | $5.3M | $5.1M |
| Free cash flow | $1.2M | $3.0M | $3.4M | $3.9M | $2.8M | $4.3M | $2.9M | $3.8M | $2.7M | $5.3M | $5.2M | $4.9M |
| Diluted shares | 3.2M | 3.2M | 3.2M | 3.2M | 3.2M | 3.3M | 3.4M | 3.5M | 3.5M | 3.6M | 3.6M | 3.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $87.5M | $87.4M | $85.8M | $84.3M | $82.2M | $83.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $210.0K | $0.00 | $241.0K | $0.00 | $269.0K |
| Total assets | $124.6M | $124.4M | $122.5M | $122.0M | $120.8M | $122.5M |
| Total liabilities | $2.5M | $4.0M | $3.3M | $3.7M | $3.3M | $5.5M |
| Shareholders' equity | $122.0M | $120.4M | $119.3M | $118.3M | $117.5M | $117.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology